Palbociclib, a specific inhibitor of CDK4/6, has recently been tested in in vitro cell line chordoma models harboring the loss of CDKN2A and showed an efficient inhibition of the tumor cell growth (41). This evidence concerns the gene CDK4 and neoplasm.